Zhejiang Yatai Pharmaceutical Co Ltd (SHE:002370) — Market Cap & Net Worth
Market Cap & Net Worth: Zhejiang Yatai Pharmaceutical Co Ltd (002370)
Zhejiang Yatai Pharmaceutical Co Ltd (SHE:002370) has a market capitalization of $570.67 Million (CN¥3.90 Billion) as of September 19, 2026. Listed on the SHE stock exchange, this China-based company holds position #11668 globally and #3331 in its home market, demonstrating a -2.61% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zhejiang Yatai Pharmaceutical Co Ltd's stock price CN¥5.23 by its total outstanding shares 745667530 (745.67 Million). Also see Zhejiang Yatai Pharmaceutical Co Ltd total assets for a full breakdown of the balance sheet.
Zhejiang Yatai Pharmaceutical Co Ltd Market Cap History: 2015 to 2026
Zhejiang Yatai Pharmaceutical Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $1.89 Billion to $570.67 Million (-8.10% CAGR). Also see cash flow conversion of Zhejiang Yatai Pharmaceutical Co Ltd for how efficiently the company converts equity into cash flow.
Zhejiang Yatai Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Zhejiang Yatai Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check current stock price of Zhejiang Yatai Pharmaceutical Co Ltd for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
2.47x
Zhejiang Yatai Pharmaceutical Co Ltd's market cap is 2.47 times its annual revenue
Latest Price to Earnings (P/E) Ratio
8.28x
Zhejiang Yatai Pharmaceutical Co Ltd's market cap is 8.28 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.57 Billion | $862.87 Million | $125.29 Million | 1.82x | 12.56x |
| 2017 | $1.55 Billion | $1.08 Billion | $202.15 Million | 1.43x | 7.68x |
| 2018 | $1.81 Billion | $1.31 Billion | $207.79 Million | 1.38x | 8.69x |
| 2019 | $701.61 Million | $707.99 Million | -$1.92 Billion | 0.99x | N/A |
| 2020 | $409.18 Million | $514.89 Million | $27.27 Million | 0.79x | 15.00x |
| 2021 | $488.83 Million | $315.13 Million | -$228.28 Million | 1.55x | N/A |
| 2022 | $536.84 Million | $373.44 Million | -$132.69 Million | 1.44x | N/A |
| 2023 | $468.10 Million | $420.64 Million | -$11.88 Million | 1.11x | N/A |
| 2024 | $332.80 Million | $405.17 Million | $34.24 Million | 0.82x | 9.72x |
| 2025 | $797.63 Million | $323.14 Million | $96.31 Million | 2.47x | 8.28x |
Competitor Companies of 002370 by Market Capitalization
Companies near Zhejiang Yatai Pharmaceutical Co Ltd in the global market cap rankings as of September 19, 2026. Review how tangible is Zhejiang Yatai Pharmaceutical Co Ltd's equity to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Zhejiang Yatai Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #613 globally with a market cap of $44.92 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #670 globally with a market cap of $40.99 Billion USD ( CN¥280.10 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #613 | GALDERMA GROUP AG | NYSE:GALDY | $44.92 Billion | $38.53 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.90 |
| #670 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $40.99 Billion | CN¥43.91 |
Zhejiang Yatai Pharmaceutical Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Zhejiang Yatai Pharmaceutical Co Ltd's market cap moved from $1.89 Billion to $ 570.67 Million, with a yearly change of -8.10%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥570.67 Million | -28.45% |
| 2025 | CN¥797.63 Million | +139.67% |
| 2024 | CN¥332.80 Million | -28.90% |
| 2023 | CN¥468.10 Million | -12.80% |
| 2022 | CN¥536.84 Million | +9.82% |
| 2021 | CN¥488.83 Million | +19.47% |
| 2020 | CN¥409.18 Million | -41.68% |
| 2019 | CN¥701.61 Million | -61.16% |
| 2018 | CN¥1.81 Billion | +16.35% |
| 2017 | CN¥1.55 Billion | -1.31% |
| 2016 | CN¥1.57 Billion | -16.76% |
| 2015 | CN¥1.89 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of Zhejiang Yatai Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $570.67 Million USD |
| MoneyControl | $570.67 Million USD |
| MarketWatch | $570.67 Million USD |
| marketcap.company | $570.67 Million USD |
| Reuters | $570.67 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Zhejiang Yatai Pharmaceutical Co Ltd
Zhejiang Yatai Pharmaceutical Co., Ltd. researches, produces, sells, and exports pharmaceutical products in China and internationally. The company offers solid dosage, cephalosporin powder injection, and freeze-dried powder injection products. It also provides various antibiotic and non-antibiotic drugs. The company was founded in 1989 and is based in Shaoxing, China.